ARTICLE | Clinical News
FDA grants Priority Review to NDA for Jazz’s Vyxeos
June 2, 2017 4:03 PM UTC
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said FDA accepted and granted Priority Review to an NDA for Vyxeos (CPX-351) to treat acute myelogenous leukemia (AML). Its PDUFA date is Sept. 30.
Jazz completed its rolling NDA submission for Vyxeos on March 31 (see BioCentury, April 17)...
BCIQ Company Profiles
BCIQ Target Profiles